TITLE:
Hepatitis C: Epidemiological, Clinical and Therapeutic Aspects in Dakar (Senegal)
AUTHORS:
Salamata Diallo, Mariéme Polele Fall, Marie Louise Bassène, Mamadou Ngoné Gueye, Mame Aissé Thioubou, Cheikh Ahmadou Bamba Cissé, Alioune Badara Fall, Abdoul Aziz Atteib Fall, Alsine Yauck
KEYWORDS:
Hepatitis C, Epidemiology, Diagnosis, Treatment, Senegal
JOURNAL NAME:
Open Journal of Gastroenterology,
Vol.12 No.4,
April
15,
2022
ABSTRACT: Viral hepatitis C is a major public health problem. The aim of our work
was to determine the epidemiological, diagnostic and treatment profiles of
patients with HCV in Dakar (Senegal). We conducted a retrospective,
descriptive, multicentre study between January 1, 2010, and December 31, 2019.
We included 26 patients. The mean age of the patients was 53.5 years [28 - 70
years] and 46.2% were males. Of the 26 patients included, 7 (26.9%) were
Senegalese, and the majority were from other African countries. Risk factors
for contamination found were surgery in 11 patients (42.3%) and blood
transfusion in 1 patient (3.8%). The mean viral load was 6.47
log IU/ml [4.26 - 7.26 log IU/ml]. Ten
patients were infected by genotype 4. No patients were co-infected with HIV or
HBV. Six patients (23.1% of patients) had significant fibrosis, of which five
(19.2% of patients) were in the stage of cirrhosis. Twelve patients (46.2%)
started treatment. Eleven were treatment-naïve and 1 did not respond to
ribavirin-pegylated interferon-based therapy after 48 weeks. Ten cases of
antiviral therapy were based on DAA and ribavirin-pegylated interferon in 2 patients. For the patients treated
with peginterferon and ribavirin, a rapid virologic response was observed at 12
weeks in one patient, and the other patient was lost to follow-up. Among
DAA-treated patients, 7 had sustained virologic responses at 12 weeks, 2 persisted,
and 1 was lost to follow-up. Moderate thrombocytopenia and weight loss were
observed in one patient receiving peginterferon and ribavirin. In our study, no
patient died on treatment and no patients developed de novo HCC during or after
DAA therapy. Conclusion: Viral hepatitis C is rare in Senegal. Despite
the progress made in the therapeutic management of viral hepatitis C, it
remains a challenge in Senegal. Indeed, DAAs are expensive and are not
marketed, which makes them inaccessible to most patients.